{"id":"streptozocin","rwe":[],"_fda":{"id":"40804eb3-12a0-f840-e063-6394a90a66ea","set_id":"f31d3bff-6fc6-c35f-e053-2995a90a596b","openfda":{"nui":["N0000000236","N0000175558"],"unii":["5W494URQ81"],"route":["INTRAVENOUS"],"rxcui":["207948","239180"],"spl_id":["40804eb3-12a0-f840-e063-6394a90a66ea"],"brand_name":["Zanosar"],"spl_set_id":["f31d3bff-6fc6-c35f-e053-2995a90a596b"],"package_ndc":["68118-100-01"],"product_ndc":["68118-100"],"generic_name":["STREPTOZOCIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["STREPTOZOCIN"],"pharm_class_epc":["Alkylating Drug [EPC]"],"pharm_class_moa":["Alkylating Activity [MoA]"],"manufacturer_name":["ESTEVE PHARMACEUTICALS, S.A."],"is_original_packager":[true]},"version":"5","how_supplied":["How supplied NDC 68118-100-01 : Each vial contains 1g Streptozocin Powder for concentrate for solution for infusion. Each carton contains 1 vial."],"effective_time":"20251006","spl_product_data_elements":["Zanosar Streptozocin STREPTOZOCIN STREPTOZOCIN SODIUM HYDROXIDE ANHYDROUS CITRIC ACID"],"health_care_provider_letter":["Dear Health Care Provider Letter DHCP1 DHCP2 DHCP3 DHCP4"],"package_label_principal_display_panel":["Vial Label vial","carton (box) label carton label"]},"tags":[{"label":"Alkylating Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AD04","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Powder","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Pancreatic Neuroendocrine Tumor","category":"indication"},{"label":"Teva Pharms Usa","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Antibiotics, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"PANCREATIC NEUROENDOCRINE TUMOUR","source":"FDA FAERS","actionTaken":"30 reports"},{"date":"","signal":"HYPOGLYCAEMIA","source":"FDA FAERS","actionTaken":"29 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"27 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"19 reports"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"18 reports"}],"commonSideEffects":[],"contraindications":["Anemia","Bacterial infectious disease","Blood coagulation disorder","Bone marrow depression","Breastfeeding (mother)","Dehydration","Diabetes mellitus","Disease of liver","Infectious disease","Kidney disease","Leukopenia","Mycosis","Pregnancy, function","Protozoal Infection","Thrombocytopenic disorder","Viral disease"],"specialPopulations":{"Geriatric use":"Clinical studies of streptozocin did not include sufficient numbers of patients aged 65 years and older to determine whether there was difference in either efficacy or toxicity as compared to younger patients. Other reported clinical experience has not identified differences in efficacy or safety between the elderly and younger patient populations. In general, dose selection for elderly patients should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased renal function and concomitant disease or other drug therapy in this population."}},"trials":[],"aliases":[],"company":"Teva","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=STREPTOZOCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:44:46.121371+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:45:06.266129+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:44:52.166311+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=STREPTOZOCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:44:52.521300+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:44.760400+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:44.760430+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:44.760435+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:44:53.977069+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:44:53.560523+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1977579/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:44:53.219675+00:00"}},"allNames":"zanosar","offLabel":[],"synonyms":["streptozocin","estreptozocin","streptozoticin","streptozotocin","zanosar"],"timeline":[{"date":"1982-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from TEVA PHARMS USA to Teva Pharms Usa"},{"date":"1982-05-07","type":"positive","source":"DrugCentral","milestone":"FDA approval (Teva Pharms Usa)"}],"aiSummary":"Streptozocin (Zanosar), marketed by Teva, is a chemotherapy agent indicated for the treatment of pancreatic neuroendocrine tumors. Its key strength lies in its unique mechanism of action, which disrupts DNA replication in cancer cells, setting it apart from other alkylating agents in its class. The primary risk is the competition from off-patent generics such as carmustine and lomustine, which may erode market share despite Zanosar's key composition patent expiring in 2028.","approvals":[{"date":"1982-05-07","orphan":false,"company":"TEVA PHARMS USA","regulator":"FDA"}],"brandName":"Zanosar","ecosystem":[{"indication":"Pancreatic Neuroendocrine Tumor","otherDrugs":[{"name":"everolimus","slug":"everolimus","company":"Novartis"},{"name":"sunitinib","slug":"sunitinib","company":"Cppi Cv"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Alkylating Activity","modality":"Small Molecule","drugClass":"Alkylating Drug [EPC]","explanation":"","oneSentence":"","technicalDetail":"Zanosar (Streptozocin) is a nitrosourea alkylating agent that exerts its cytotoxic effects by cross-linking DNA strands, thereby inhibiting DNA replication and transcription."},"commercial":{"launchDate":"1982","_launchSource":"DrugCentral (FDA 1982-05-07, TEVA PHARMS USA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2483","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=STREPTOZOCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=STREPTOZOCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:42:02.281107","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:45:06.266230+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"carmustine","drugSlug":"carmustine","fdaApproval":"1977-03-07","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lomustine","drugSlug":"lomustine","fdaApproval":"1976-08-04","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"uracil mustard","drugSlug":"uracil-mustard","fdaApproval":"1962-09-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"streptozocin","indications":{"approved":[{"name":"Pancreatic Neuroendocrine Tumor","source":"DrugCentral","snomedId":717919005,"regulator":"FDA","eligibility":"patients with symptomatic or progressive metastatic disease"}],"offLabel":[{"name":"Carcinoid syndrome","source":"DrugCentral","drugName":"STREPTOZOCIN","evidenceCount":40,"evidenceLevel":"moderate"}],"pipeline":[]},"currentOwner":"Teva Pharms Usa","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"carmustine","brandName":"carmustine","genericName":"carmustine","approvalYear":"1977","relationship":"same-class"},{"drugId":"lomustine","brandName":"lomustine","genericName":"lomustine","approvalYear":"1976","relationship":"same-class"},{"drugId":"uracil-mustard","brandName":"uracil mustard","genericName":"uracil mustard","approvalYear":"1962","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03813407","phase":"PHASE3","title":"An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-02","conditions":["Hyperkalaemia"],"enrollment":140,"completionDate":"2030-02-21"},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":["Neuroendocrine Tumors"],"enrollment":116,"completionDate":"2022-04-25"},{"nctId":"NCT07083232","phase":"PHASE4","title":"The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-10-30","conditions":["Diabetic","Myocardial Infarction"],"enrollment":50,"completionDate":"2024-11-30"},{"nctId":"NCT07036796","phase":"PHASE2","title":"Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-07-04","conditions":["Diabetic Peripheral Neuropathy","Diabetic Neuropathy","Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients"],"enrollment":60,"completionDate":"2026-07-04"},{"nctId":"NCT02246127","phase":"PHASE3","title":"Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2014-10-27","conditions":["Neuroendocrine Tumors"],"enrollment":141,"completionDate":"2021-07-12"},{"nctId":"NCT03351296","phase":"PHASE2","title":"Two Chemotherapy Regimens Plus or Minus Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-06-26","conditions":["Pancreatic Cancer"],"enrollment":140,"completionDate":"2028-12"},{"nctId":"NCT04217590","phase":"PHASE3","title":"Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-16","conditions":["Hyperkalemia"],"enrollment":134,"completionDate":"2022-01-03"},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":["Urothelial Carcinoma","Bladder Cancer","Urinary Bladder Neoplasms"],"enrollment":8,"completionDate":"2019-10-23"},{"nctId":"NCT03758014","phase":"PHASE2,PHASE3","title":"Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients","status":"UNKNOWN","sponsor":"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd","startDate":"2018-11-27","conditions":["GBM"],"enrollment":200,"completionDate":"2021-04-30"},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":["Chemotherapy Induced Nausea and Vomiting"],"enrollment":307,"completionDate":"2013-08-16"},{"nctId":"NCT00609765","phase":"PHASE2","title":"Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-08","conditions":["Pancreatic Cancer"],"enrollment":1,"completionDate":"2008-03"},{"nctId":"NCT00094497","phase":"PHASE3","title":"Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)","status":"COMPLETED","sponsor":"Collaborative Group for Adrenocortical Carcinoma Treatment","startDate":"2004-06","conditions":["Carcinoma, Adrenal Cortical"],"enrollment":304,"completionDate":"2010-12"},{"nctId":"NCT00004688","phase":"PHASE2","title":"Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms","status":"COMPLETED","sponsor":"Emory University","startDate":"1996-08","conditions":["Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Mixed Gliomas","Glioblastoma Multiforme","Recurrent Brain Tumor"],"enrollment":35,"completionDate":"1998-07"},{"nctId":"NCT00448136","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-07","conditions":["Neoplasms"],"enrollment":83,"completionDate":"2011-11"},{"nctId":"NCT00602082","phase":"PHASE2","title":"Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2005-08","conditions":["Gastrointestinal Carcinoid Tumor","Islet Cell Tumor"],"enrollment":84,"completionDate":"2009-12"},{"nctId":"NCT00003543","phase":"PHASE1","title":"Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-06","conditions":["Colorectal Cancer"],"enrollment":18,"completionDate":"2002-08"},{"nctId":"NCT00001165","phase":"PHASE2","title":"Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1978-09","conditions":["Islet Cell Adenoma","Neoplasm Metastasis","Zollinger Ellison Syndrome"],"enrollment":999,"completionDate":"2003-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Powder","formulations":[{"form":"POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Zanosar"},{"form":"POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Zanosar"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146432","MMSL":"1423","NDDF":"002663","UNII":"5W494URQ81","VUID":"4018094","CHEBI":"CHEBI:9288","VANDF":"4018094","INN_ID":"3824","RXNORM":"10114","UMLSCUI":"C0038432","chemblId":"CHEMBL1977579","ChEMBL_ID":"CHEMBL1651906","KEGG_DRUG":"D05932","DRUGBANK_ID":"DB00428","PDB_CHEM_ID":" STZ","PUBCHEM_CID":"29327","SNOMEDCT_US":"16915004","MESH_DESCRIPTOR_UI":"D013311"},"formularyStatus":[],"originalProduct":{"form":"POWDER, FOR SOLUTION","route":"INTRAVENOUS","company":"Teva Parenteral Medicines, Inc.","brandName":"Zanosar","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1982-","companyName":"Teva Pharms Usa","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"21%"},"publicationCount":2439,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AD04","allCodes":["L01AD04"]},"biosimilarFilings":[],"originalDeveloper":"Teva Pharms Usa","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Teva Pharms Usa","companyId":"teva","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-05-07T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1982-05-07T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1982-05-07T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1982-05-07T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1982-05-07T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1982-05-07T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:45:06.266230+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}